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doi:10.1016/j.ejvs.2009.08.010Abstract Genome-wide approaches, including microarray-based expression profiling, DNA
linkage studies and genetic association studies, offer an unbiased way to identify genetic risk
factors and biological processes leading to discoveries, which might help in the development of
new diagnostic and therapeutic approaches for a wide range of diseases. Currently, the
number of published genome-wide analyses for aneurysms and peripheral artery diseases is
still limited, and it is difficult to generalise about the disease pathogenesis or genetic risk
factors contributing to these diseases. Large multicentre studies are needed to provide suffi-
cient statistical power, and replication studies are essential before these findings are used for
defining clinical policies of diagnosis and treatment. The biggest future challenge will be to
translate the genomic information to the clinical settings so that it will improve our under-
standing of the disease processes, help us to develop better diagnostic tools and lead to the
design of new ways to manage aneurysms and peripheral artery disease in the era of persona-
lised medicine. Characterisation of diseases at the molecular level is likely to lead to more
accurate diagnoses and the use of ‘genomic nosology’ of diseases.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Developments in genomic and genetic technology and
analysis are allowing rapid advances in human disease
research, including diseases of the vasculature outside of71 5592; fax: þ570 271 6701.
r.edu (G. Tromp).
ty for Vascular Surgery. Publishethe heart and brain. The unbiased nature of high-
throughput, whole-genome approaches provides the
promise of improved nomenclature, development of new
screening procedures and therapeutic interventions.1
We review here the progress on genome-wide, high-
throughput analyses of mRNA and genomic DNA for the study
of aneurysms and peripheral artery disease (PAD). The
translationof genomic information to usable clinical toolswill
be facilitated by initiatives such as the Genomic Applicationd by Elsevier Ltd. All rights reserved.
Genomics of Peripheral Vascular Disease 677in Practice and Prevention (GAPP) Network spearheaded by
the Office of Public Health Genomics at the Centers for
Disease Control and Prevention,2 Public Health Genomics
EuropeanNetwork (PHGEN). (www.phgen.eu) andTheHealth
Technology Assessment International (HTAi; www.htai.org)
located in Edmonton, Canada. A new field called Public
Health Genomics has been created and the first international
journal carrying the name of the field was launched this year
(www.kanger.com). A suggestion has also been made to
develop ‘systemsmedicine’ through the interaction between
systems biology and medicine to lead to integrated and
interdisciplinary education and clinical care.3
Genome-wide microarray-based expression
profiling provides new clues to pathobiology of
vascular diseases
Genome-wide expression profiling using microarrays can be
a useful tool in dissecting disease pathogenesis (Table 1,
Figs. 1 and 2), but many critical issues related to this
technique and the interpretation of the results have been
recognised and need special attention.4,5 This approach
requires tissue samples, which have been collected in
a way that minimises RNA degradation. Typically, tissue
samples to be used for RNA isolation are collected into
a preservative solution sold under a commercial name
RNAlater see Ref.6 Control samples should be matched for
sex, age and ethnicity to avoid gene expression differencesTable 1 Different genome-wide approaches to study periphera
Approach Advantages
Microarray-based mRNA
expression profiling
No prior knowledge about
pathogenesis needed
Unbiased
Genome-wide DNA linkage
analysis
No prior knowledge about
pathogenesis needed
Unbiased
DNA is easily available
Good statistical power
Only modest number of
markers needed
Genome-wide association
study (GWAS)
No prior knowledge about
pathogenesis needed
Unbiased
DNA is easily available
Sensitive for low to moderate
effect size
Good coverage with a large
number of markers
Excellent estimate of location
For details on each approach, see text.due to these variables. The sources of control tissue are
limited, usually restricted to autopsies and organ trans-
plant donors.
With respect to aneurysms and PAD, microarrays have
been used to study the differences between atherosclerotic
and lesion-free parts of thoracic aorta of organ trans-
plants,7 as well as blood8 and tissue9 samples from patients
with thoracic aortic aneurysms. They have also been used
to analyse human aneurysmal tissue6,10 and peripheral
blood11 samples obtained from patients with abdominal
aortic aneurysm (AAA) as well as tissue samples from animal
models of AAA.12,13 Microarrays were also recently used to
analyse femoral artery samples obtained from patients with
varying degrees of PAD.14
Expression studies in aneurysms and PAD have several
limitations. One specific sample-related limitation is that
the diseased tissue comes from late-stage disease, when
the disease has progressed far enough to warrant surgical
intervention. A time course of gene expression during
disease development could yield valuable results, but this is
not possible with humans.
Bias may be introduced in microarray studies when using
tissues derived from autopsies as controls. Extensive
quality control, however, revealed little or no detectable
differences between surgical aortic tissue samples and
control RNA derived from autopsy samples.6 A similar result
was obtained in a study of carotid artery samples obtained
during surgeries versus those from autopsies.15 Postmortem
changes in RNA have been studied and shown to affect RNAl vascular diseases.
Disadvantages
Labor-intensive and technically difficult
Expensive
Specialized bioinformatics tools required
Tissue samples usually difficult to obtain
Samples from end-stage disease provide
no information about process
Annotation of genes is incomplete
Protein levels correlate poorly with mRNA levels
Families with multiple affecteds are needed
‘‘Affecteds only’’ analysis is necessary for
robustness (diagnostic uncertainty about unaffecteds)
For late-age-at-onset diseases difficult to
find multigenerational families
Insensitive for low to moderate effect size
Poor estimate of location
Large sample sizes needed
Expensive and large number of markers needed
Current designs do not cover all regions
of the genome equally well
Requires specialized instrumentation for genotyping
678 G. Tromp, H. Kuivaniemiintegrity, but this is both tissue and time dependent, and
can be modest.16,17 Despite these limitations, postmortem
tissues have been used successfully for expression
studies.6,15
The incompleteness of gene annotations is yet another
limitation of microarray studies, since only a fraction of theIsolate  RNA
Tissue
Label cDNA
Hybridize to Probes
Detect Fluorescence
Laser
Detecto
Figure 1 Outline of microarray expression studies. Tissue specim
isolated from the tissue and cDNA synthesized which is labeled, usu
tissue (red fluor for diseased and green for control). DNA sequenc
substrate, a printed cDNA array is illustrated with each circle repre
a control specimen are mixed and hybridized to the arrayed sequ
array is detected by shining a laser on the array and detecting the
fluors is shorter than the emitted light and is filtered out). The spots
red. Spots that are more green have higher relative levels of that
relative levels in the diseased tissue. The experiments can also b
comparing the absolute signal intensities. Reproduced with permisgenes have known functional categories and are part of
known pathways featured in the Kyoto Encyclopedia of
Genes and Genomes (KEGG).18 Considerably more genes
have Gene Ontology (GO) annotations.19 If the raw data are
deposited into publicly available databases such as the
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.r
Array
ens, diseased (left), and normal (right) are collected. RNA is
ally with a different fluorophor for the diseased and the control
es representing gene sequences are arrayed on some physical
senting a different gene. The labeled cDNA from a diseased and
ences. The relative amount of labeled cDNA hybridized to the
emitted light (the wavelength of the laser used to excite the
on the array are illustrated as a mixture of pure green and pure
gene in the control and spots that are more red have higher
e performed by hybridizing each sample to its own array and
sion from Tromp & Kuivaniemi, 2008.36
Figure 2 Arteries have distinct mRNA expression profiles based on microarray studies. Gene expression data from 50 tissue
samples were obtained from GEO, preprocessed using R and Bioconductor, and clustered using average linkage with Pearson’s
correlation as the metric. The sub-cluster of genes with the greatest difference between vascular and non-vascular tissues is
shown. Genes are represented by rows with the gene dendogram at left. Samples are represented by columns with the sample
dendogram rotated 90 clockwise and show at right. With the exception of Aorta sample 10, the vascular samples all cluster
together. The genes are likely important for vascular biology in health and disease.
Genomics of Peripheral Vascular Disease 679gov/projects/geo/), future re-analysis of the data, partic-
ularly of the genes that currently lack annotation, will be
possible. Recent identification of various functional non-
coding RNA species such as micro RNA and long non-coding
RNA adds to the incompleteness of annotation and even of
representation on the arrays.20
The usefulness of microarray-based data will depend on
the ability to integrate these data with the other available
resources. In silico transcriptomics (IST) database is avail-
able through interactive web interface at GeneSapiens
website21 (www.genesapiens.org), although it is more
suitable for biologists than clinical investigators.DNA linkage studies: a useful genome-wide tool for
family-based studies
In genetics, the term linkage indicates that a particular
genetic marker is co-inherited with a phenotype. Linkage of
a disease phenotype and a marker means that the two are
located closely on the same physical piece of DNA. The
closer the two loci (the disease and the marker) occur on
a piece of DNA, the less frequent crossovers occur between
them during meioses, and the more tightly the two are
linked. A marker is a polymorphic region of DNA such as
a microsatellite repeat marker or a single nucleotide
polymorphism (SNP).The premise underlying the use of DNA linkage analysis is
that the disease is heritable. Use of linkage analysis to
identify the genetic causes of late-age-at-onset, diseases
such as AAA and PAD was until recently, difficult at best
(Table 1). Several technological advances have drastically
changed the outlook. First, the interest in carrying out
diagnostic imaging, such as ultrasonography screening
studies on relatives of AAA patients, has made it possible to
detect far more family members with AAA prior to rupture,
and there are far more live, affected members available for
genetic studies. Second, the development of highly infor-
mative markers that can be easily analysed using poly-
merase chain reaction (PCR) has greatly enhanced the
power of any linkage study. Third, the large number of
linkage studies being performed on human diseases has
refined and advanced the methods and models for linkage
analyses. Fourth, there have been theoretical and applied
advances in linkage methodology itself. Linkage is limited,
however, to detection of alleles (specific gene variants)
which have a large effect, therefore, manifesting the
disease in families.
To circumvent the problem of not being able to identify
families with extended pedigrees and affected individuals
in several generations, the sib pair (or other relative pair)
approach to genetic linkage can be used (see Ref.22). Sib
pairs are useful when studying complex traits because of
a feature unique to sib relationships (brotherebrother;
680 G. Tromp, H. Kuivaniemibrotheresister; sisteresister): they can share 0, 1 or 2
alleles at the locus. The distribution of the relationships
expected by chance is simple and leads to predictions that
can be tested without specifying the mode of inheritance
(model-free methods). Sib pairs are easier to collect than
extended families, and usually there are more of these
relationships available than many or most other extended
family relationships. It is, however, less powerful than the
extended pedigree approach and depending on factors such
as the locus-specific risk, the density of markers, locus and
marker heterogeneity, between 300 and 800 sib pairs might
be needed to identify susceptibility loci.23
Genome-wide DNA linkage analysis has been carried out
for AAA using affected-relative-pair approach, and the
results provided evidence for genetic heterogeneity and
the presence of susceptibility loci for AAAs on 19q13 and
4q31.24 These loci have been designated as AAA1 and AAA2,
respectively, in the Online Mendelian Inheritance in Man
(OMIM) database (http://www.ncbi.nlm.nih.gov/omim/).
The linkage intervals are large and contain numerous bio-
logically feasible positional candidate genes, the study of
which is needed to define the risk alleles located in these
regions.
Genome-wide association studies (GWASs)
identify common genetic risk factors for
vascular diseases
GWAS provides an approach to identify genetic risk factors
for a complex disease, such as aneurysms or PAD, by gen-
otyping on the order of half a million SNPs for thousands of
cases and controls (Table 1).25,26 It is not biased by the
need for prior knowledge about the disease pathogenesis
and will, therefore, give a good understanding of the
genetic architecture of a disease. GWAS is more feasible
than family-based DNA linkage studies for complex, late-
age-at-onset and deadly diseases such as AAA, because
samples from extended families are not required. Even
though such studies are now technically feasible, thanks to
cataloguing of millions of SNPs in the human genome and
improvements in high-throughput genotyping techniques,
they are expensive and have a number of unresolved
challenges, including the problem of correcting for multiple
testing (Tables 1 and 2).
As of March 2009, approximately 400 GWASs for various
disease phenotypes and human traits (e.g., eye color, hair
colour and height) have been published. A summary of theseTable 2 Comparison of genome-wide approaches to candidate
Feature Approach
Genome-Wide Stud
Prior knowledge
about pathogenesis
Not needed
Bias Unbiased
Sample size >1000 cases and c
Cost Expensive
Technical aspects Specialized instrum
Statistical analyses Sophisticated
a Sample size is dependent on the effect size of the genetic varianstudies with results having p-values 5 108 is available
online at www.genome.gov/GWAStudies.27 One of these
studies related to nicotine dependence28 and an association
was found with an SNP (rs1051730) on chromosome 15q24. The
SNP is located in a genomic region with a cluster of genes
encoding nicotinic acetylcholine receptors. When tested for
associationwith lung cancer and PAD, both phenotypes showed
an association with the SNP suggesting a role for nicotine
addiction in other diseases and a geneeenvironment interac-
tion.28 Another recently identified common genetic variant
located on chromosome 9p21 was found to be associated with
many vascular phenotypes, including coronary artery disease,
intracranial aneurysms andAAA, suggesting a commonpathway
involving the initial vascular injury for these phenotypes.29
A significant practical limitation for GWAS is cost. One
approach to reducing cost is to use pooled DNA samples.
Genotyping of individual DNA samples is then performed for
SNPs in regions with putative associations in the pooled DNA
genome scan. This approach was used for AAA and a locus
on chromosome 3p12.3 was identified.30
Future challenges and opportunities
During the past two decades, the field of human genetics has
undergone a revolution from studying mostly single-gene
disorders to studying common complex diseases using
genome-wide techniques. This has led to a huge increase in
the amount of genomic and genetic data available in public
databases, and increased the complexity of statistical and
computational analyses. The challenge now will be to take
full advantage of the available information by expanding the
analyses beyond genes and biological pathways already
known to be involved in the disease process. The genome-
wide approaches offer an unbiased way to identify genetic
risk factors and biological processes leading to discoveries,
which might help in the development of new tools for diag-
nostics and therapeutic approaches. It is also reasonable to
expect that these data will help to assess the usefulness of
therapies, for example, microarray-based gene expression
showing that treated tissue is more similar to control (non-
diseased) tissue than untreated diseased tissue; or tech-
niques used in pharmacogenomics identifying those patients
likely to benefit from drug treatment due to decreased
adverse effects or enhanced therapeutic effects.
Currently, the number of published genome-wide analyses
for aneurysms and PAD is still limited, and it is difficult to
generalise about the disease pathogenesis or genetic riskgene approach.
y Candidate Gene Study
Needed
Educated guess
ontrolsa > 500 cases and controlsa
Cheap
entation Simple
Simple and straightforward
t under study.
Genomic Nosology of Disease
Bioinformatics
Association
Clinical
(Phenotype)
Risk Intervals
(few to 100’s of genes)Functional
Studies
Molecular 
Analyses
Linkage
Figure 3 Genomic nosology of disease. Bioinformatics has
the potential to increase the number of diseases for which
molecular and functional studies elucidate the disease mech-
anism. Traditional approaches to studying genes contributing
to disease risk involve identification of risk intervals containing
few to many genes by use of linkage or association. Identifying
the risk genes and characterising them by molecular and
functional studies has been a rate-limiting process. Bio-
informatics can reduce the number of candidate genes to
a shorter list more quickly speeding up the process and leading
to a pool of information that can be used to generate
a genomic nosology of disease. Black arrows indicate tradi-
tional processes, red arrows those facilitated by bio-
informatics. Thickness of arrows indicates rate.
Genomics of Peripheral Vascular Disease 681factors contributing to these diseases. Large multicentre
studies are needed to provide sufficient statistical power and
replication studies areessential before thesefindings areused
for defining clinical policies of diagnostics and treatment.
The biggest future challenge will be to translate the
genomic information to the clinical settings so that it will
improve our understanding of the disease processes, help
us to develop better diagnostic tools and lead to the design
of new ways to manage aneurysms and PAD in the era of
personalised medicine.31,32 This is a non-trivial challenge. It
has been 50 years since the molecular defect of sickle-cell
disease was elucidated,33 but the knowledge has proved
less useful than hoped for. There are some prospects for
successful translation of genetic and genomic information
to clinical practice: CYP2C19 variants are important modi-
fiers of response to clopidogrel,34 and prospective studies
of warfarin dosing based on CYP2C9 and VKORC1 genotypes
are ongoing.35 These variants are not yet approved as
guides for dosing and the findings need to be replicated.
Nevertheless, characterisation of diseases at the molecular
level is likely to lead to more accurate diagnoses and the
use of ‘genomic nosology’ of diseases (Fig. 3).
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